- Jefferies analyst Faisal Khurshid upgraded BeOne Medicines to a "buy" rating with a target price of $380.00, citing strong revenue potential for Brukinsa in both the short and long term.
- He anticipates a strong performance in Q2, supported by promising data from early-stage assets entering late-stage development, and sees lower risks from competing CLL treatments.
- RBC Capital also maintains a "buy" rating for the stock with a higher target price of $451.00, indicating growing investor interest amid easing market pressures.
